| Literature DB >> 32536869 |
Qing-Xia Gan1, Jin Wang1, Ju Hu1, Guan-Hua Lou1, Hai-Jun Xiong1, Cheng-Yi Peng1, Qin-Wan Huang1.
Abstract
Cancer has become a significant public health problem with high disease burden and mortality. At present, radiotherapy and chemotherapy are the main means of treating cancer, but they have shown serious safety problems. The severity of this problem has caused further attention and research on effective and safe cancer treatment methods. Polysaccharides are natural products with anti-cancer activity that are widely present in a lot of plants, and many studies have found that inducing apoptosis of cancer cells is one of their important mechanisms. Therefore, this article reviews the various ways in which plant polysaccharides promote apoptosis of cancer cells. The major apoptotic pathways involved include the mitochondrial pathway, the death receptor pathway, and their upstream signal transduction such as MAPK pathway, PI3K/AKT pathway, and NF-κB pathway. Moreover, the paper has also been focused on the absorption and toxicity of plant polysaccharides with reference to extant literature, making the research more scientific and comprehensive. It is hoped that this review could provide some directions for the future development of plant polysaccharides as anticancer drugs in pharmacological experiments and clinical researches.Entities:
Keywords: apoptosis; cancer; natural products; pathway; plant polysaccharides
Year: 2020 PMID: 32536869 PMCID: PMC7267062 DOI: 10.3389/fphar.2020.00792
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Mitochondrial apoptotic pathway in cancer induced by plant polysaccharides. with different colors indicate inhibition/reduction, and with different colors indicate increase/promotion.
Figure 3The regulation of other apoptosis signal conduction in cancer by plant polysaccharides with different colors indicate inhibition/reduction, and with different colors indicate increase/promotion.
Effects of plant polysaccharides on apoptosis in cancer.
| Drugs | Monosaccharide composition/structure | Model | Dose and treat time | Activity and type of cancer | Apoptotic pathway | Involved mechanism | Ref |
|---|---|---|---|---|---|---|---|
| Galatose, arabinose, rhamnose (6:3:1) | HepG2 cells. | 0–1,000μg/ml, 24, 48, and 72 h | AR: 65.1% | Mitochondrial Pathway | Bax↑; MMP↓; Cytochrome c↑; Caspase-9, Caspase-3↑; annexin V-positive↑ | ( | |
| MSC-2cells | 0.25, and 0.5mg/ml, 72 h | AR: 12.1% | Mitochondrial Pathway | Bax, Caspase 9↑; Bcl-2↓; P-NF-κB p65 ↑; TLR4↑ | ( | ||
| Arabinose, galactose (4:2) | CNE-2 cells | 0–200μg/ml, 24, 48, 72 h | AR: 47.65% | Mitochondrial Pathway | MMP↓; Cytochrome c↑; Caspase-3/9↑ | ( | |
| Rhamnose, arabinose, glucose, galactose, Glucuronic acid (0.03:1.00:0.27:0.36:0.30) | SW620 cells | 0. 1-1. 0 g/L, 48 h | AR: 37. 63% | Mitochondrial Pathway | Bax/Bcl-2↑; Caspase-3, Caspase-9, Cytochrome c ↑ | ( | |
| A | Mice injected with MDA-MB-231 cells | Orally, 200, 400 mg/kg for 21 days | AR: 62. 87% | Mitochondrial Pathway | Bcl-2↓; Bax, Caspase-9, Caspase-7↑ | ( | |
| A | CNE-1, CNE-2, and SUNE-1 | 10–80μg/ml, 48 h | AR: Over 40% | Mitochondrial Pathway | Bcl-2↓; Bax, Caspase-3, Caspase-9↑ | ( | |
| Mice injected with CNE-2 cells | 40mg/kg (i.p.) twice a week for 4 weeks | ||||||
| Glucose, rhamnose, arabinose, xylose, mannose, galactose (12.1: 0.3: 0.6: 1.0:1.0: 1.7.) | MGC-803 cells | 0–800μg/ml, 24 h | AR: 20.60% | Mitochondrial Pathway | Bax/Bcl-2↑; Cytochrome c↑; Caspase-9/-3↑; PARP↓; ROS↑ | ( | |
| Glucose, galactose, arabinose (6.0: 3.0: 1.0) | U-2 OS cell | 25, 50, and 100μg/ml, 24, 48, and 72 h | CV: About 50% | Mitochondrial Pathway | DNA fragmentation; Bax/Bcl-2↑; MMP↓; Cytochrome c↑; Caspase-9 and Caspase-3↑; PAPR↓ | ( | |
| C6 cells | 50, 100, and 200μg/ml, 48 h | CV: 19.1% | Mitochondrial Pathway | MMP↓; Cytochrome c↑; Capase-3, Caspase-9↓; PARP↓ | ( | ||
| Glucose | PC cells | 25–100μg/ml, 48 h | AR: 73.2% | Mitochondrial Pathway | Bax/Bcl-2↑; Caspae-3↑; miR-93↓ | ( | |
| Rhamnose, arabinose, galactose, glucose, mannose, galacturonic acid (0.67: 7.67: 10.83: 3.83: 4.00: 1.00) | Mice injected with H22 cells | Orally, 50 and 250mg/kg for 3 weeks | TIR: 58.85% | Mitochondrial Pathway | Bcl-XL, Mcl-1↓; Caspase 3↑ | ( | |
| Fructose, xylose, mannose, glucose, galacose (25.0, 25.0, 10.0,12.5,12.5) | CNE-2 cells | 12.5–100.0μg/ml, 48 h | AR: 42.85% | Mitochondrial Pathway | Bcl-2↓; p53↑ | ( | |
| F1; Glucose, Galactose, Xylose, Mannose (5.1,11.5,74.5,3.2) | Siha and LNCap cells | 100–1,000μg/mL, 24, 48 and 72 h | CV: Under 60% | Mitochondrial Pathway | COX-2 ↓; DNA fragmentation; MMP ↓; p53 expression↑; Caspase 3↑; Bcl-2 family genes↓; Cytochrome c↑ | ( | |
| Glucose, galactose, and mannosein (2.3:1.2:1.2) | SCC-25 cells | 50, 100, and 200μg/mL, 48 h | AR:64.07% | Mitochondrial Pathway | Bax/Bcl-2↓; MMP↓; Cytochrome c↑; Capase-3 and Caspase-9↑; PARP↓ | ( | |
| Glucose, galactose, mannose (2.0: 1.0: 1.0) | A549 cells | 25, 100, and 200μg/ml, 48 h | AR:66.08% | Mitochondrial Pathway | Caspase-9 and -3↑; Cytochrome c↑; Bax↑ | ( | |
| Mice injected with A549 cells | 50, 100 mg/kg for 15 days | ||||||
| Rhamnose, glucose, galactose, arabinose, mannose (4.31:4.16:4.49:9.22:27.8) | Hep2 cells | 25–800μg/ml, 24 h | AR: 67.45% | Mitochondrial Pathway | Caspase-3, Caspase-8, Caspase-9↑; Bcl-2↓ | ( | |
| MDA-MB-231 cells | 5–100 µg/ml, 24 h | AR: 50 % | Mitochondrial Pathway | Cip1/p21, Kip1/p27↑; cyclins D1, D2, E1 transcripts, Cdk2, Cdk4, Cdk6↓; Bax transcripts↑; Bcl-2↓; Caspase-3↑; ROS↑ | ( | ||
| L-galactose, L-arabinose, D-glucose (34.43, 26.39, 21.80) | Pc-3 cells | 50–500 µg/ml, 48 h | AR: 20.22% (Pc-3), | Mitochondrial Pathway | mRNA Cyclin A/B1/D1/E1↓; CDK-1/2/4/6, p15/16/21/27↓; p53↑; Survivin, Bcl-2↓; Caspase-3, Caspases-8 and Caspases-9↑; Cytochrome c, Bax↑; Bcl-2↓; PARP↓ | ( | |
| Total sugar, uronic acid, and protein (72.4, 19.5, 9.7) | U-2 OS cells | 0–400μg/ml, 24–96 h | AR: 49.73% | Mitochondrial Pathway | Bax/Bcl-2↑; MMP↓; Cytochrome c↑; Caspase-9 and Caspase-3↑; PARP↓ | ( | |
| Glucose, galactose | HeLa cell | 50–1,000μg/mL, 24, 48, and 72 h | TIR: 50.28% | Mitochondrial Pathway | Cytochrome c↑; Caspase-9, Caspase-3↑; wild-type p53↑ | ( | |
| Galactose, mannose, glucose, arabinose (2.02:2.05:1.00:0.52) | HepG2 cells | 100, 200, and 400μg/ml, 24, 48, and 72h | AR: 70.3% | Mitochondrial Pathway | Bax↑; Bcl-2↓; Caspase-9, Caspase-3↑; PARP↓ | ( | |
| Cholangiocarcinoma cell lines | 25–200μg/ml, 24 h | AR: 78.9% | Mitochondrial Pathway | Bax/Bcl-2↑; Caspase-9 and Caspase-3↑; 67LR, Cdc42↓ | ( | ||
| MCF cells | 0.04, 0.08, 0.17, 0.34, 0.68, 1.36mg/ml, 48 h | AR: 54.5% | Mitochondrial Pathway | Bcl-2↓; MMP-9 ↓; TIMP 1↓ | ( | ||
| HN-6 cells | 0-1.28 mg/mL, 24–72 h | TIR: About 50% | Mitochondrial Pathway | Bcl-2, COX-2↓; Bax, cleaved Caspase-3↑ | ( | ||
| HL-60 cells | 50, 100, 150, 200, and 400μg/ml, 24 h | AR: 70.2% | Mitochondrial Pathway | MMP↓; Cytochrome c↑; Bcl-2 protein and mRNA↓; Bax↑; Caspase-9, Caspase-3↑ | ( | ||
| Galactofuranose, arabinose (64.6:11.2) | MCF7 and MDA-MB-231 cells | 0–500μg/ml, 24 h | Breast cancer | Mitochondrial Pathway | ROS↑; Nuclei damage; Caspase3/9↑ | ( | |
| A549 cells | 0–1.5 mg/ml for 12 and 24 h | AR: 28.8% | Mitochondrial Pathway | MMP↓; ROS↑; P53, Bax↑; Bcl-2↓; Caspase-3, Caspase-9↑; PARP↓; G2/M phase↓ | ( | ||
| Transgenic zebrafish | 1, 4mg/ml for 48 h | ||||||
| Se-containing polysaccharides from | 93.7% carbohydrate | T24 cells | 50–200μg/ml, 24, 48 or 72 h | AR: 70.3% | Mitochondrial Pathway | Bax↑; Bcl-2↓; MMP↓; Caspase-9, Caspase-3↑; PARP↓ | ( |
| Carbohydrate (93.7%), uronic acid (2.1%), and 3.7μg/g of Se | HEY and SKOV3 cells | 0–1,000μg/ml, 24 h | AR: 41.4% (HEY) | Mitochondrial Pathway | cyclin D1, Bcl-2, MMP-9↓; PARP↓; Caspase-3 and Caspase-9↑; β-catenin↓; p-β-catenin↑ | ( | |
| Female mice injected with HEY cells | Orally, 400 mg/kg for 28 days | ||||||
| 4T1 cells | 10% medicated serum, 24h | AR: over 30% | Mitochondrial Pathway | Bcl-2↓; Bax↑; Bcl-2/Bax↓; Cytochrome c↑; Caspase-3↑ | ( | ||
| Mice injected with 4T1 cells | 150, 300, 600 mg/kg for 7 days | ||||||
| Hep2 cells | 50, 100, 200, 400 mg/L,48h | AR:30.9% | Mitochondrial Pathway | Caspase-3↑; p53↑; Bcl-2/Bax↓; NO↑; TNF↑ | ( | ||
| Hep2 cells | 100, 200, and 400 ug/ml, 24 h | AR: 60% | Mitochondrial Pathway | Cleavage of pro-Caspase-3, pro-Caspase-8, and pro-Caspase-9↑; DR5, Bax↑; Bcl-2↓ | ( | ||
| L-rhamnose, D- arabinose, D-mannose, D-glucose, D-galactose (3.64: 5.37: 3.04: 61.03: 26.91) | HepG2 cells | 0–0.4 mg/ml, 12 h | AR: 16.84% | Mitochondrial Pathway | Bax, Fas, FasL↑; Caspase-3, p21, p53↑; Bcl-2↓ | ( | |
| MLL - ALL cells | 100, 500, 1,000mg/l, 12 h | AR: Over 25% | Mitochondrial Pathway | DR5↑; Caspase-8, Bid, Caspase-3, Caspase-9, Bad↑; Bcl-2↓ | ( | ||
| 89.75% total carbohydrate | MCF-7 cells | 50–1,000μg/mL, 24 h | AR:29.7% | Death receptors Pathway | NO and TNF-α↑; Bax/Bcl-2↑ | ( | |
| D-galactose and 3,6-anhydro- L -galactose (57.38:41.2) | A549 cells | 0–100 µg/ml, 72 h | AR: Over 5% | Death receptors Pathway | Fas/FasL↑ | ( | |
| Rhamnose, galacturonic acid, glucose, galactose, and arabinose (13: 13: 1: 7: 12) | A549 cells | 31.2–1,000μg/mL, 48 h | AR:40% | Death receptors Pathway | p-AKT↓; Caspase-3↑; Fas, FasL↑; Bax↑; Bcl-2↓ | ( | |
| A549 and YTMLC-90 cells | 0.04 to 2.56 mg/ml, 24, 48, and 72 h | TIR: About 80% | PI3K/AKT Pathway | Bax mRNA, Caspase-3↑; CDC25B, cyclin B1↓; AKT, p-AKT, PI3K↓; TNF- α, IL-6↑ | ( | ||
| Mice injected with A549 cells | 15 to 135 mg/kg (i.p.) for 30 days | ||||||
| A novel polysaccharide derived from algae | MCF-7 cells | 1–1,000 µg/ml, 48 h | AR: Over 16% | MAPK Pathway | P-JNK↑; Phosphorylation and expression of p53↑; Caspase-9 and Caspase-3↑; ROS↑ | ( | |
| MG63 cells | 1, 5, 10, 20mg/ml, 24 h | AR: About 10% | MAPK Pathway | miR-133a↑; cyclinD1↓; p21↑; Bcl-2↓; Bax↑; Caspase-9 and Caspase-3↑ | ( | ||
| SKOV3 cells | 50–1,600μg/ml, 24, 48, and 72 h | AR: Over 40% | MAPK Pathway | Bcl2↓; Bax, Caspase-3↑; JNK1/2↑ | ( | ||
| RCC cell lines (Caki-1, Caki-2, and ACHN) | 25–800μg/ml, 48 h | AR: About 50% | MAPK Pathway | MMP↓; Cytochrome c↑; Bax/Bcl-2↑; Caspase-3/9↑; PARP↓; p- ERK1/2↓ | ( | ||
| H22 cells | 10, 20, and 40μg/ml for 48 h | AR: 43.3% | PI3K/AKT Pathway | PTTG1 mRNA↓; p-AKT↓; p-p38MARK ↑ | ( | ||
| ASPC-1, PANC-1 cells | 50–400 μg/ml, 24 h | RA: Over 30% (ASPC-1) | MAPK Pathway | P-AKT, p-ERK, MMP-9↓; | ( | ||
| MG-63 cell | 20, 10, 5, and 1mM, 24 h | AR: 57% | MAPK Pathway | P-p38, p-AKT↓; Bax, Caspase3↑; Bcl-2↓ | ( | ||
| U87 cells | 0.2, 1, 5, and 10 mg/ml, 72 h | CV: 44.6% | MAPK Pathway | P-p53↑; p-p38, p-JNK↑; p-AKT, p-ERK↓ | ( | ||
| Glucose, xylose, arabinose, rhamnose (8.82:1.92:1.50:1.00) | HT-29 cells | 0–150μg/ml, 48 h | AR: 49.17% | MAPK Pathway | P-JNK↑; Ras↓; p-ERK↓; NF-κB↓; Bcl-2↓; Bax↑; Cytochrome c, Caspase-8, Caspase-9↑ | ( | |
| AGS cells | 0–600μg/ml, 24h | AR: Over 20% | PI3K/AKT Pathway | p-AKT ↓; MMP-9↓ | ( | ||
| Xylose, mannose (85:15) | AGS cells | 0–5 mg/ml, 24 h | CV: About 40% | PI3K/AKT Pathway | Bad, Caspase-3↑; Bcl-2↓; p-IGF-IR↓; Akt↓ | ( | |
| HepG2 cells | 6.25, 12.5, and 25 mg/ml, 72 h | AR: 20.1% | PI3K/AKT Pathway | Bax, cleaved-Caspase-3, Klotho↑; Ki67, Bcl-2, p-PI3K/PI3K, p-AKT/AKT↓ | ( | ||
| Glucose, rhamnose, arabinose mannose (8.54:1.83:1.04:0.42.) | HOS cells | 100, 200, and 400μg/ml, 24 h | AR: 55.3% | PI3K/AKT Pathway | MMP↓; ROS↑; PI3K, p-AKT↓ | ( | |
| Mice injected with H22 cells | Orally, 25, 50, and 75mg/kg for 10 days | TIR: Over 85% | PI3K/AKT Pathway | P53 DNA and protein↑; p-PI3K and p-AKT↓ | ( | ||
| H22 and BEL7402 cells | 2–1,250μg/ml, 24, 48 h | ||||||
| Arabinose, mannose, glucose, galactose (1.31:1.00:3.59:1.59) | HT29 cells | 10, 20, 40, and 80 mg/l, 24 h | AR: Over 30% | PI3K/AKT Pathway | Bax, Bak↑; Bcl-2, FN↓; E-cadherin mRNA↑; N-cadherin, vimentin mRNA, p-AKT/AKT↓ | ( | |
| Glucose, galactose, mannose, rhamnose, and arabinose (2.1:5.2:2.1:1.0:1.2) | C6 cells | 50–1,000μg/ml, 24, 48, and 72 h | Glioma | PI3K/AKT Pathway | DAN damage; Bax/Bcl-2↑; Caspase-3, Caspase-8, Caspase-9↑; AKT↓ | ( | |
| SD rats injected with C6 cells | Orally, 50, 100, and 200 mg/kg for 2 weeks | ||||||
| SH-SY5Y cells | 0–500μg/ml, 48 h | AR: Over 10% | PI3K/AKT Pathway | Bax↑; miR-675↓; Bcl-2↓; cleaved Caspase-3, Caspase-9↑; p-PI3K, p-AKT, p-JAK1, p-STAT3↓ | ( | ||
| HeLa cells | 100 and 200μg/ml, 24 h | AR: About 0.06 | TLR4/NF-κB Pathway | Bax↑; Bcl-2↓; TLR4, MyD88, TRAF6, AP-1, NF-κB subunit P65↓ | ( | ||
| OVCAR-3 cells | 0.1–1.6 mg/mL, 24, 48, 72 h | AR: 75.6% | NF-κB Pathway | Bcl-2↓; Bax, Cytochrome c, Caspase-3, Caspase-9↑; NF-κB↓ | ( | ||
| T47D cells | 12.5, 25, 50, and 100 µg/ml,24 h | Breast cancer | CREB Pathway | CREB↑; Bax↑; Mcl-1↓ | ( | ||
| Mice injected with T47D cells | 0.2 mg/kg (i.p.) for 4 weeks | ||||||
| Hepatocellular carcinoma cells | 0.1,0.5,1mg/ml, 3 days | AR: Over 10% | Notch Pathway | Bcl-2↓; Bax↑; Caspase-3 and -8↑; Notch1↓ | ( | ||
| Galactose, mannose, glucose, arabinose (2.02:2.05:1.00:0.52) | HepG2 cells | 200, 400µg/ml, 48h | AR: 71.5% | JAK/STAT Pathways | P-JAK2↓; SHP-1↑ | ( | |
| Female mice injected with HepG2 cells | 0.25, 0.5, and 1.0 mg/kg (i.p.) for 18 days | ||||||
| Galactose, arabinose, glucose, galacturonic acid (3.7:1.6:0.5:5.4) | HGC-27 cells | 100,200,400µg/ml, 48 h | AR: 65.0% | Mitochondrial Pathway | Twist, AKR1C2↓; NF1↑; Caspases 3, 9↑; PARP↓; Fas, FasL ↑; Caspase-8↑; Bid↓ | ( | |
| Se-containing polysaccharides from | Xylose, arabinose, fucose, mannose, ribose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose | MDA-MB-231 cells | 100, 400μg/ml, 24 h | AR: Over 30% | Mitochondrial Pathway | Bax, p53, Puma and Noxa↑; Bcl2↓; Bax/Bcl2↑; Caspases 3/9↑; PARP↓; CDC25C, CDC2 and Cyclin B1↓ | ( |
| Female mice injected with MDA-MB-231 cells | Orally, 100,400 mg/kg for 30 days. | ||||||
| U251 cells | 0.2 mg/ml, 48 h | Glioma | Mitochondrial Pathway | Bcl-2↓; Bax, cleaved-Caspase-3↑; E-cadherin↑; TGF-β1, p-Smad2, p-Smad3↓ | ( | ||
| Mice injected with U251 cells | 50 mg/kg | ||||||
| 2-O-grailsine-β-xylose (4→6)-α-glucose (1→4) -β-mannose osamine | ZR-75-1 cells | 76.4, 152.8, 305.6, and 611.2 mg/L,24–96h | AR: 40.1% | ERα Pathway | Expression and nuclear translocation of ERα↑; Caspase-3, -8, -9↑; PARP↓ | ( |
↑ indicates increase/promotion/activation while ↓ indicates inhibition/reduction/inactivation. AR, Apoptosis rate; TIR, Tumor inhibition rate; CV, Cell viability.
Figure 2Death receptor apoptotic pathway in cancer induced by plant polysaccharides. with different colors indicate inhibition/reduction, and with different colors indicate increase/promotion.